One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Time to Debunk an Urban Myth? The “Abscopal Effect” With Radiation and Anti–PD-1
Tanguy Y. Seiwert, MD1 and Ana P. Kiess, MD, PhD2
doi : 10.1200/JCO.20.02046
no. 1 (January 01, 2021) 1-3.
Parsing the Paradox of Myelodysplastic Syndromes
Mikkael A. Sekeres, MD, MS1
doi : 10.1200/JCO.20.02964
no. 1 (January 01, 2021) 4-6.
Treating Advanced Head and Neck Cancer When Cisplatin Is Not an Option
Sachin R. Jhawar, MD1; Marcelo Bonomi, MD2; and Paul M. Harari, MD3
doi : 10.1200/JCO.20.02720
no. 1 (January 01, 2021) 7-12.
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.
Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
Maha Hussain , MD1; Daniel Lin , MD2; Fred Saad , MD3; Neha Vapiwala, MD4; Brian Francis Chapin, MD5; Howard Sandler , MD, MS6; ...
doi : 10.1200/JCO.20.02268
no. 1 (January 01, 2021) 13-16.
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
Hans-Joachim Schmoll , MD, PhD1; Alexander Stein , MD2; Eric Van Cutsem, MD, PhD3; Timothy Price, MBBS, DHlthSc4; Ralf D. Hofheinz, MD5; Bernard Nordlinger, MD6; ...
doi : 10.1200/JCO.20.01740
no. 1 (January 01, 2021) 17-29.
The PETACC 6 trial investigates whether the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine improves disease-free survival (DFS) in locally advanced rectal cancer.
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
Sean McBride, MD, MPH1; Eric Sherman, MD2,3; C. Jillian Tsai, MD, PhD1; Shrujal Baxi, MD, MPH2; Jahan Aghalar, MD1; Juliana Eng, MD1; ...
doi : 10.1200/JCO.20.00290
no. 1 (January 01, 2021) 30-37.
The objective response rate (ORR) for single-agent anti–programmed death receptor 1 (anti–PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). We aimed to test whether radiotherapy may act synergistically with anti–PD-1 therapy to improve response through the abscopal effect.
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer
Maria Gebre-Medhin , MD, PhD1; Eva Brun, MD, PhD1; Per Engstr?m, PhD1; Hedda Haugen Cange, MD, PhD2; Lalle Hammarstedt-Nordenvall , MD, PhD3; Johan Reizenstein, MD4; ...
doi : 10.1200/JCO.20.02072
no. 1 (January 01, 2021) 38-47.
We performed an open-label randomized controlled phase III study comparing treatment outcome and toxicity between radiotherapy (RT) with concomitant cisplatin versus concomitant cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC; stage III-IV according to the Union for International Cancer Control TNM classification, 7th edition).
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
David P. Steensma, MD1; Pierre Fenaux, MD, PhD2; Koen Van Eygen, MD3; Azra Raza, MD4; Valeria Santini, MD5; Ulrich Germing, MD, PhD6; ...
doi : 10.1200/JCO.20.01895
no. 1 (January 01, 2021) 48-56.
Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC transfusion dependent and have experienced relapse after or are refractory to erythropoiesis-stimulating agent (ESA) have limited treatment options. High telomerase activity and human telomerase reverse-transcription expression in clonal hematopoietic cells have been reported in patients with MDS. Imetelstat, a first-in-class competitive inhibitor of telomerase enzymatic activity, targets cells with active telomerase. We report efficacy, safety, and biomarker data for patients with LR MDS who are RBC transfusion dependent and who were relapsed/refractory to ESAs.
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D. DiNardo , MD1; Anthony S. Stein, MD2; Eytan M. Stein, MD3; Amir T. Fathi, MD4; Olga Frankfurt, MD5; Andre C. Schuh, MD6; ...
doi : 10.1200/JCO.20.01632
no. 1 (January 01, 2021) 57-65.
Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested that addition of azacitidine to ivosidenib enhances mIDH1 inhibition–related differentiation and apoptosis.
Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
James C. Glasbey, MBBCh, BSc, MRCS, PGCert1; Dmitri Nepogodiev, MBBCh1, Joana F.F. Simoes, MD1; Omar Omar, MSc1; Elizabeth Li, MBBCh, MRCS2; Mary L. Venn, MBBCh, BSc, MRCS, ...
doi : 10.1200/JCO.20.01933
no. 1 (January 01, 2021) 66-78.
As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
Stephen R. D. Johnston, PhD1; Roberto Hegg, MD, PhD2; Seock-Ah Im, MD, PhD3; In Hae Park, MD4; Olga Burdaeva, MD5; Galina Kurteva, MD6; ...
doi : 10.1200/JCO.20.01894
no. 1 (January 01, 2021) 79-89.
Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)–positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy. This updated article reflects minor numerical corrections in some secondary efficacy analyses that resulted from programming errors and that do not change the major conclusions of the study.
Minimally Invasive Esophagectomy: Time to Reflect on Contemporary Outcomes
Bas P. L. Wijnhoven, MD, PhD and Sjoerd M. Lagarde, MD, PhD
doi : 10.1200/JCO.20.01620
no. 1 (January 01, 2021) 90-91.
Hybrid Minimally Invasive Esophagectomy to the Rescue: A Valid Alternative for Phased Dissemination of TMIE?
Frederiek Nuytens , MD, Thibault Voron , MD, PhD, and Guillaume Piessen , MD, PhD
doi : 10.1200/JCO.20.01964
no. 1 (January 01, 2021) 91-92.
Reply to B. P. L. Wijnhoven et al and F. Nuytens et al
Sheraz R. Markar, MRCS(Eng), MSc, MA, MBBChir and Mark I. van Berge Henegouwen, MD, PhD
doi : 10.1200/JCO.20.02354
no. 1 (January 01, 2021) 92-93.
Reply to B. P. L. Wijnhoven et al and F. Nuytens et al
Michael O. Meyers, MD
doi : 10.1200/JCO.20.02390
no. 1 (January 01, 2021) 93-94.
